Following HLA-matched alloSCT, the curative graft versus tumor (GVT) reactivity is mediated by donor-derived T cells recognizing minor histocompatibility antigens (MiHA) expressed by the malignant patient cells. The gene discussed is XIAP; the disease is neoplasm.